Skip to main content
Figure 5 | Molecular Cancer

Figure 5

From: A novel small molecule that selectively inhibits glioblastoma cells expressing EGFRvIII

Figure 5

a) Effects on caspase 3 and 7 expression in 897 and 878 cells by treatment with 1 μM NSC-154829. Cells were exposed to 1 μM NSC-154829 and then caspase 3 and 7 levels measured as outlined in the Materials and Methods. Caspase levels were normalized to DMSO-only treated controls and expressed as fold increases. Each experiment was performed three times and each time in sextuplicate. There was borderline significance between the increase in caspase 3 and 7 levels in the mutant cells compared to wild type (p = 0.05). b) Effects of 1 μM NSC-154829 on caspase 3 and 7 levels in the D54/54E cell lines. While there was an increase in caspase activity in the D54E cells in response to NSC-154829 treatment compared to D54s, this difference was not significant. Each experiment was performed three times in sextuplicate. c) Dose-response effect of NSC-154829 on levels of caspase 3 and 7 in the D54 and D54E cell lines. Treatment with 5 μM of NSC-154829 nearly doubled levels of caspase 3 and 7 in both the wild type (D54) and mutant (D54E) cells. d) Treatment with 10 μM of NSC-154829 doubled levels of caspase 3 and 7 in the mutant cells, but had little effect on the wild-type cell line (*** p < 0.0001). Caspase levels for each cell line were normalized to DMSO-only treated controls and expressed as fold-change. Each assay was performed three times in sextuplicate.

Back to article page